MorphoSys AG (MORG.DE)
* Financial year 2019 guidance, updated in July, confirmed: revenues in range of 65 mln to 72 mln eur
BERLIN/FRANKFURT, May 22 The following are some of the factors that may move German stocks on Wednesday:
BERLIN, April 30 The following are some of the factors that may move German stocks on Tuesday:
* GECKO IS A PHASE 2 STUDY TESTING A SUBCUTANEOUS FORMULATION OF MOR106 IN COMBINATION WITH TOPICAL CORTICOSTEROIDS IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
FRANKFURT, Feb 25 German biotech firm Morphosys is in talks with potential partners to bring its debut drug, a therapeutic antibody against leukaemia, to Europe.